Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation.

D W van Bekkum

    Transplantation Proceedings
    |March 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Bone marrow transplantation shows promise for SCID and leukemia, but requires refined techniques and donor selection. Further research into graft-versus-host disease (GVHD) and late complications is crucial for improving patient outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling.

    Bone marrow transplantation·2014
    Same author

    Observations upon a change in an enzymatic process in burns.

    Quarterly journal of experimental physiology and cognate medical sciences·2014
    Same author

    Call for case histories of BMT in patients with coincident schizophrenia.

    Bone marrow transplantation·2013
    Same author

    Call for case histories of BMT in patients with coincident schizophrenia.

    Leukemia·2013
    Same author

    Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation.

    Bone marrow transplantation·2003
    Same author

    Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases.

    Journal of leukocyte biology·2002

    Area of Science:

    • Immunology
    • Hematology
    • Transplantation Medicine

    Background:

    • Severe Combined Immunodeficiency (SCID) and leukemia are serious conditions requiring advanced treatment modalities.
    • Bone marrow transplantation (BMT) is a key therapy, but faces challenges including graft-versus-host disease (GVHD) and donor compatibility.
    • Current BMT protocols require refinement for optimal patient outcomes, especially for those without matched sibling donors.

    Purpose of the Study:

    • To explore advancements in bone marrow transplantation for SCID and leukemia.
    • To identify strategies for mitigating complications such as GVHD.
    • To investigate methods for improving donor selection and transplantation efficacy.

    Main Methods:

    • Utilizing purified stem-cell concentrates for SCID patients lacking compatible siblings.

    Related Experiment Videos

  • Continuing attempts at restoration with fetal liver cells for SCID.
  • Investigating the role of intestinal microflora in GVHD.
  • Analyzing factors predicting GVHD in sibling pairs.
  • Exploring autologous stem cell collection for leukemia treatment.
  • Developing methods for selecting compatible unrelated donors.
  • Using animal models (dogs, rhesus monkeys) for histocompatibility typing research.

    • Main Results:

    • Purified stem cells offer potential for SCID patients without sibling donors, necessitating technique refinement.
    • Fetal liver cell transplantation remains a viable option for SCID.
    • Strict infection control and reverse isolation are vital for patients at risk of GVHD.
    • Intestinal microflora may exacerbate GVHD, warranting further investigation.
    • Identifying GVHD predictors is key to utilizing reductive measures effectively.
    • Autologous stem cell transplantation is a promising alternative to allogeneic BMT for leukemia, potentially avoiding GVHD.
    • Improved histocompatibility typing is essential for expanding donor pools.

    Conclusions:

    • Refined stem cell purification and monitoring are needed for BMT in SCID.
    • Comprehensive infection control is critical for patients at risk of GVHD.
    • Understanding and mitigating GVHD, including the role of microflora, is paramount.
    • Developing methods for selecting compatible unrelated donors will significantly increase BMT accessibility.
    • Further research into late complications and toxicity of BMT regimens for leukemia is necessary.